{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-003573","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2022-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.806075+00:00","generated_at":"2026-06-26T23:15:30.705529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Spruce Biosciences reports Q4/FY2021 net loss of $9.2M/$42.3M; cash $121.4M","bullets":["Cash, cash equivalents and investments of $121.4M as of Dec 31, 2021; expected to fund operations into Q2 2024.","R&D expenses for FY2021: $30.7M, up from $23.9M in 2020; net loss widened to $42.3M from $29.5M.","Appointed Will Charlton, M.D., M.A.S., as Chief Medical Officer in March 2022; he previously served at 89bio.","Topline safety data from Cohort 1 of Phase 2 pediatric classic CAH study expected by 1H 2023; PCOS Phase 2 topline also by 1H 2023.","CAHmelia-203 (adult classic CAH, poor disease control) topline by 2H 2023; CAHmelia-204 (good disease control) by 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-003573","json":"https://secwatch.observer/filing/0000950170-22-003573.json","markdown":"https://secwatch.observer/filing/0000950170-22-003573.md","text":"https://secwatch.observer/filing/0000950170-22-003573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017022003573/0000950170-22-003573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017022003573/sprb-20220314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:15:30.705529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}